EirGenix Secures $152 M Licensing Deal for EG1206A Breast‑Cancer Biosimilar from Sandoz
EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX:...
Humanwell Initiates Phase 2 Trial of HW231019 Tablets for Post‑Abdominal Surgery Analgesia
Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase 2 clinical...
Bio‑Sincerity Secures XPO1 Inhibitor Deal for BIOS‑0629, Aims at Solid‑Tumor Expansion
Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology...
Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth
Bayer AG (ETR: BAYN) announced on November 12 2025 that its third‑quarter 2025 (2025Q3) performance matched prior‑year...
FDA Announces New ‘Plausible‑Mechanism’ Pathway to Rapid Approvals for Rare Disease Treatments
The U.S. Food and Drug Administration (FDA) announced on Wednesday a landmark regulatory shift that could...
Complete Genomics and SOPHiA Genetics Join Forces to Deliver End‑to‑End Oncology Validation on MGI’s T1+ Sequencing Platform
Complete Genomics, the U.S. subsidiary of MGI Technologies (SHA: 688114), announced today a strategic collaboration...
Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders
Degron Therapeutics, a China‑based pioneer in protein‑degradation therapies, today announced the signing of a Letter...
Adicon Holdings, Crown Bioscience, and Global Lab Services Forge New Integrated Platform for Oncology Translational Research
Adicon Holdings Ltd. (HKG: 9860), a leading independent clinic laboratory (ICL) service provider in China,...
AbbVie to End 11‑Year R&D Alliance with Alphabet‑Owned Calico Labs
AbbVie Inc. (NYSE: ABBV) announced today that it will terminate its long‑standing collaboration agreement with...
ChengDa Biotechnology, IMCAS, and Beijing Key Laboratory for Synthetic Immunology Forge New Frontiers in Vaccine Manufacturing
Liaoning ChengDa Biotechnology Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences (IMCAS)...
Sun‑Novo, Byterna, and CAR‑T/CircRNA Collaboration Propel In‑Vivo Gene‑Therapy Frontiers
Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. today disclosed a strategic capital injection of RMB 15 million into...
Suzhou Forlong Biotech, Shanghai Henlius, and Engineered Cytokine Immunotherapy Collaboration Announced
Suzhou Forlong Biotechnology Co., Ltd. today revealed a strategic partnership with Shanghai Henlius Biotech, Inc....
GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies
GemPharmatech Inc., (SHA: 688046) a global leader in pre‑clinical research solutions and genetically‑engineered mouse models,...
Jinling Pharmaceutical, Nanjing Gulou Hospital, and CD16a Tech‑Transfer Deal Bolsters NK‑Cell Oncology
Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing...
Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D
Jacobio Pharma Ltd. (HKG: 1167) announced today that its subsidiary Beijing Jacobio Pharmaceuticals Co., Ltd....
Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution
Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn. Bhd. (wholly‑owned by Pharmaniaga Berhad) today announced a...
Shandong Buchang’s Luzhou Unit Moves to Secure Exclusive Distribution of Epo‑IgG Fusion in Vietnam
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today that its subsidiary Luzhou Buchang will enter...
AnkeBio and PersonGen Ink Capital‑Increase Deal, Secure Exclusive Greater‑China Agency for PA3‑17 CAR‑T Therapy
Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today...
Chongqing Precision Biotech Wins NMPA Approval for pCAR‑19B – China’s First Humanised CD19 CAR‑T Therapy for Pediatric B‑ALL
Chongqing Precision Biotech Co., Ltd. announced that its pCAR‑19B cell‑based product has received National Medical...
Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)
Sino-US biotech Laekna Therapeutics (HKG: 2105) and Qilu Pharmaceutical Co., Ltd. announced today an exclusive...